# TODO: Remaining Stagemigration Features

## Summary

The stagemigration module has completed **Phase 1** (Foundational Features), **Phase 2** (Advanced Validation & Clinical Utility), **Phase 3** (Clinical Integration Features), and **Phase 4-5** (Advanced Features - Enhanced Statistical Analysis Suite).

This document lists the **remaining advanced features** from Phases 3-6 that could further enhance the module for research and specialized use cases.

---

## **Phase 3: Cutting-Edge & Developmental Features**

### **1. New Stage Development Tools**
- **Optimal Cut-point Determination:** For a continuous variable (e.g., tumor size), find the optimal cut-point that creates the most statistically significant separation in survival outcomes. Include corrections for multiple testing.
- **Systematic Stage Grouping Optimization:** Use bootstrap resampling to systematically test different ways of grouping TNM categories or other variables to find the combination that maximizes prognostic performance.

### **2. Advanced Survival Modeling** 
- **Competing Risks Analysis:** Implement Fine-Gray models and Cumulative Incidence Function (CIF) plots to correctly handle scenarios with multiple event types (e.g., cancer death vs. other causes).

### **3. Model Interpretability & Reporting**
- **Model Interpretability (SHAP):** Integrate Shapley Additive Explanations (SHAP) to generate plots that explain which factors are driving the predictions of a complex model.

---

## **Phase 4: Enhanced Features from ChatGPT Stage Migration Analysis**

### **1. Advanced Will Rogers Phenomenon Analysis**
- **Temporal Comparison Framework:** Compare stage-specific survival across different time periods to detect artifacts vs. real improvements

### **3. Real-World Clinical Examples Integration**
- **Cancer-Specific Templates:**
  - Pancreatic cancer AJCC 8th edition validation templates
  - Colorectal cancer lymph node examination effects
  - Thyroid cancer age threshold migration analysis
  - Lung cancer imaging advancement effects
- **Era Comparison Tools:** Temporal analysis accounting for diagnostic advancement bias
- **Morphologic Feature Integration:** Tools for adding new prognostic factors (size, invasion patterns, etc.)

### **4. Methodological Validation Framework**
- **External Validation Tools:** Framework for validating staging systems on independent cohorts
- **Sensitivity Analysis:** Robust analysis under different assumptions and scenarios

### **5. Clinical Decision Support Enhancements**
- **Cost-Effectiveness Considerations:** Framework for evaluating staging system implementation costs

### **6. Advanced Quality Control**
- **Censoring Pattern Analysis:** Evaluation of censoring mechanisms and their impact

---

## **Phase 5: Advanced Features from Claude Stage Migration Analysis**

### **1. Advanced Cox Modeling Enhancements**
- **Frailty Models for Clustering:** Mixed-effects Cox models (coxme) for multi-institutional data with center-specific random effects

### **2. Enhanced Stage Migration Quantification**
- **Migration Correction Methods:** Apply probability-weighted expectations to adjust for migration effects

### **3. Regulatory and Clinical Guidelines Integration**
- **REMARK Guidelines Adherence:** 20-item checklist for prognostic marker studies
- **TRIPOD Statement Compliance:** 27-item checklist for prediction model development
- **Registry Compatibility Assessment:** Ensure new staging aligns with cancer registry systems
- **Timeline Projection Tools:** Estimate development-validation-implementation timeline (5-7 years)

### **4. Advanced Validation Methodologies**
- **Transportability Assessment:** Evaluate performance across different populations and settings
- **Temporal Validation:** Assess performance on data from different time periods
- **Geographic Validation:** Test staging system across different geographic regions

### **5. Complex Survival Data Handling**
- **Interval Censoring Support:** icenReg implementation for events detected between visits
- **Informative Censoring Detection:** Tests and adjustments for non-random censoring patterns
- **Fine-Gray Models:** Competing risks regression with cmprsk package integration
- **Multi-State Models:** Complex transitions between disease states (msm package)
- **Cure Models:** Mixture models for populations with cured fraction

### **6. Enhanced Discrimination Metrics**
- **Concordance Probability Estimates:** Alternative concordance measures for heavily censored data
- **Win Ratio Analysis:** Composite endpoint analysis for staging comparison

### **7. Clinical Decision Analysis Integration**
- **Clinical Utility Index:** Combine sensitivity/specificity with disease prevalence
- **Number Needed to Treat:** Calculate NNT based on staging-guided interventions

### **8. Machine Learning Integration**
- **Random Survival Forests:** Non-parametric alternative to Cox models
- **Deep Learning Survival Models:** Neural network approaches for complex interactions
- **Ensemble Methods:** Combine multiple models for robust predictions
- **Feature Importance Analysis:** SHAP values and permutation importance
- **Cross-Validation for ML:** Proper CV strategies for survival ML models

### **9. Reporting and Visualization Excellence**
- **CONSORT-Style Flow Diagrams:** Patient flow through staging analysis
- **Calibration Belt Plots:** Advanced calibration visualization with confidence regions
- **Nomogram Generation:** Clinical prediction tools from staging models
- **Interactive Web Reports:** Shiny-based interactive staging comparison dashboards

### **10. Sample Size and Power Analysis**
- **Multi-Stage Power Analysis:** Power calculations for hierarchical staging comparisons
- **Simulation-Based Power:** Monte Carlo methods for complex staging scenarios
- **Adaptive Sample Size:** Interim analysis and sample size re-estimation

### **11. Biomarker Integration Framework**
- **Biomarker Cutpoint Optimization:** Optimal thresholds for continuous biomarkers
- **Multi-Marker Panels:** Combine multiple biomarkers with anatomic staging
- **Cost-Effectiveness Analysis:** Evaluate biomarker addition from economic perspective
- **Missing Biomarker Handling:** Multiple imputation for incomplete biomarker data
- **Validation of Biomarker Staging:** Specific validation approaches for integrated staging

---

## **Phase 6: Advanced Features from Gemini Stage Migration Analysis**

### **1. Systematic Stage Development Framework**
- **Bootstrap Model/Cutpoint Selection Method:** Systematic search across candidate staging systems using bootstrap-estimated criteria
- **Orderly Progressive Condensation:** Define T and N category groupings with partial ordering constraints
- **Minimum Stage Size Constraints:** Ensure each stage contains ≥5% of sample for statistical stability
- **Eligible System Generation:** Algorithm to generate all valid candidate staging systems adhering to pre-specified rules

### **2. Advanced Optimal Cutpoint Determination**
- **Minimum p-value/Maximum Statistic Approach:** Conservative method for optimal cutpoint selection
- **Selection Interval Constraints:** Exclude outer 10-20% of distribution to maintain statistical power
- **Multiple Testing Corrections:** Adjust for multiple comparisons when testing various cutpoints
- **Outcome-Oriented Cutpoints:** Maximally selected rank statistics via maxstat package
- **Cutpoint Variability Assessment:** Bootstrap variability estimation for cutpoint stability

### **3. Model Interpretability Enhancement**
- **SHAP Summary Plots:** Visualize direction and magnitude of feature impacts across dataset
- **SHAP Bar Plots:** Rank features by average absolute SHAP values for importance hierarchy
- **SHAP Dependence Plots:** Reveal non-linear relationships and feature interactions
- **Individual Force Plots:** Patient-specific prediction explanations showing feature contributions
- **Global vs Local Interpretability:** Framework for both population-level and individual-level explanations

### **4. Stage Migration Quantification Tools**
- **Immune Response Hypothesis Testing:** Assess if lymph node count reflects immune response vs. understaging
- **Lymph Node Yield Analysis:** Correlate node count with survival independent of positivity
- **Temporal Migration Tracking:** Monitor stage distribution changes over diagnostic eras
- **Multi-Factor Migration Analysis:** Separate effects of diagnostic improvement vs. biological factors

### **5. Clinical Implementation Framework**
- **Online Platform Deployment:** Web calculator implementation for real-time risk assessment
- **Electronic Health Record Integration:** Embed staging tools within clinical workflows
- **Clinical Workflow Optimization:** Streamline staging assessment at point of care

### **6. Advanced Performance Metrics Implementation**
- **Landmark Analysis Framework:** Convert survival to binary outcomes at clinically relevant timepoints
- **Explained Variation (π̂):** Landmark-based measure of prognostic power
- **Concordance Probability (K̂):** Generalized C-index accounting for all observation pairs
- **Cure Rate Modeling:** Special handling for diseases with potential cure fraction

### **7. R Package Integration Suite**
- **SurvMetrics Integration:** Enhanced C-index calculations for tied survival data
- **calibmsm for Multistate Models:** Advanced calibration assessment for complex transitions
- **maxstat via survminer:** Optimal cutpoint determination with survival outcomes
- **cutpointr Framework:** Tidy approach to cutpoint optimization with bootstrapping

### **8. Biomarker and Additional Factor Integration**
- **Inflammation-Based Biomarkers:** NAR, SII, PNI integration into staging
- **Pathology Grade Integration:** Incorporate tumor differentiation into staging
- **Molecular Alterations:** BRAF mutations, tumor markers (CEA) as staging factors
- **Treatment Response Factors:** Surgery status, adjuvant therapy considerations
- **Comorbidity Adjustment:** Account for patient factors affecting prognosis

### **9. Quality Assurance and Regulatory Compliance**
- **Missing Data Pattern Analysis:** Identify and handle systematic missingness
- **Cancer-Specific Validation:** Tailored approaches for different malignancy types

### **10. Advanced Visualization Suite**
- **Interactive Dashboard Components:** Dynamic visualizations for exploring results

### **11. Clinical Translation Tools**
- **Implementation Timelines:** Project 5-7 year development-validation-adoption cycle
- **Training Module Development:** Educational resources for new staging criteria
- **Performance Monitoring Framework:** Track real-world staging system performance
